NICE update

Last update: 04 August 2014

For more information on BSR's involvement with NICE contact our Clinical Affairs Director, Ali Rivett. For more information on NICE consultations and their work generally, visit the National Institute of Health and Clinical Excellence (NICE) website.

BSR is very grateful to the members who, as our nominated Clinical Experts, put a considerable amount of time and effort into responding to the many NICE appraisals and consultations received every year by BSR.

Guidelines and Quality Standards published in June 2013

BSR contributed to pegloticase for treating severe debilitating chronic tophaceous gout (ID308) and endorsed the recommendations made by the National Osteoporosis Society in respect of Guideline CG161 on Falls in Older People.

We also contributed to NICE's Quality Standards for Rheumatoid Arthritis.

Appraisals and Guidelines in progress

BSR has contributed, or is planning to contribute to the following:

  NICE Methods of Technology Appraisal Consultation

NICE approach to biosimiliars

TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis [Including a review of technology appraisal 143 and technology apprasisal 233]

Bisphosphonates for preventing osteoporotic fragility fractures [ID782]

Belumimab for the treatment of active autoantibody-positive systemic lupus erythematosus [ID416]

Rituximab in combination with corticosteroids for treatment of anti-neutorphil cytoplasmic antibody-associated vasculitis [ID567]

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab for the treatment of Rheumatoid Arthritis [MTA ID537]

Ustekinumab for treating active and progressive psoriatic arthritis [ID 607]

Low back pain (clinical guideline review)

Osteoarthritis guideline update

Etanercept for the treatment of juvenile ideopathic arthritis (proposed review of NICE technology appraisal guidance)

Canakinumab for the treatment of Juvenile Inflammatory Arthritis [ID 533]

Pegloticase for treating severe debilitating chronic tophaceous gout [ID308]
For further details on BSR’s work with NICE, please contact Ali Rivett.